Thalidomide suppresses NF-κB activation induced by TNF and H2O2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester

Journal of Immunology

Volumn 168, Issue 6, 2002, Pages 2644-2651

  Majumdar, Sekhar ^a   Lamothe, Betty ^a   Aggarwal, Bharat B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERAMIDE; HYDROGEN PEROXIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; PHORBOL ESTER; THALIDOMIDE; TUMOR NECROSIS FACTOR;

ANGIOGENESIS; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IMMUNOMODULATION; INFLAMMATION; LEUKEMIA CELL LINE; PRIORITY JOURNAL; REPORTER GENE; T LYMPHOCYTE;

EID: 0037087402     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.168.6.2644     Document Type: Article

References (70)

1. Immunomodulation by thalidomide: Systematic review of the literature and of unpublished observations
2. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity
3. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes
4. Thalidomide as an antiTNF-α inhibitor: Implications for clinical use
5. Thalidomide on the comeback trail
6. Thalidomide: Rationale for renewed use in immunological disorders
7. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum
8. Thalidomide inhibits the replication of human immunodeficiency virus type I
9. Thalidomide and thalidomide analogs reduce HIV type 1 replication in human macrophages in vitro
10. Effects of thalidomide on HIV-associated wasting syndrome: A randomized, double-blind, placebo-controlled clinical trial
11. Thalidomide for the treatment of AIDS-associated wasting
12. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection
13. The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection
14. The treatment of microsporidial diarrhoea with thalidomide
15. Effect of thalidomide on the inflammatory response in cerebrospinal fluid in experimental bacterial meningitis
16. Adjunctive thalidomide therapy of childhood tuberculous meningitis: Possible antiinflammatory role
17. Thalidomide for the treatment of chronic graft-versus-host disease
18. Treatment of severe esophageal Crohn's disease with thalidomide
19. Thalidomide protects mice against LPS-induced shock
20. Thalidomide is an inhibitor of angiogenesis
21. Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro
22. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent highgrade gliomas
23. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
24. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy
25. The role of tumor necrosis factor α in the pathophysiology of human multiple myeloma: Therapeutic applications
26. Effect of thalidomide on chemokine production by human microglia
27. Effect of cytokine modulation by thalidomide on the granulomatous response in murine tuberculosis
28. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogs that are potent inhibitors of TNF-α
29. Thalidomide stimulates T cell responses and interleukin 12 production in HIVinfected patients
30. + subset
31. Thalidomide inhibits tumor necrosis factor α, decreases nitric oxide synthesis, and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats
32. Rel/NF-κB/IκB family: Intimate tales of association and dissociation
33. Activation of the transcription factor nuclear factor-κB in human inflamed synovial tissue
34. Cell specific effects of glucocorticoid treatment on the NF-κBp65/IκBα system in patients with Crohn's disease
35. Role of nuclear factor-κB in gastric ulcer healing in rats
36. Tumor necrosis factor α and interleukin I stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor κB
37. Involvement of the transcription factor NF-κB in tubular morphogenesis of human microvascular endothelial cells by oxidative stress
38. Assay for redox-sensitive transcription factor
39. Human chorionic gonadotropin suppresses activation of nuclear transcription factor-κB and activator protein-I induced by tumor necrosis factor
40. Leflunomide suppresses TNF-induced cellular responses: Effects on NF-κB, activator protein-I c-Jun N-terminal protein kinase, and apoptosis
41. Activation of NF-κB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-κB-inducing kinase: Identification of a novel TRAF6 interaction motif
42. Oxidative stress induces NF-κB nuclear translocation without degradation of IκBα
43. lck is required for ceramide-induced but not tumor necrosis factor-induced activation of NF-κB, AP-1, JNK, and apoptosis
44. IκBα degradation is not a requirement for the X-ray-induced activation of nuclear factor κB in normal rat astrocytes and human brain tumour cells
45. Ischemia/reperfusion injury in the liver of BALB/c mice activates AP-1 and nuclear factor κB independently of IκB degradation
46. Pervanadate-induced nuclear factor-κB activation requires tyrosine phosphorylation and degradation of IκBα: Comparison with tumor necrosis factor-α
47. Tyrosine phosphorylation-dependent activation of NF-κB: Requirement for p56 LCK and ZAP-70 protein tyrosine kinases
48. Distinct signal transduction pathways mediate NF-κB induction by 1L-1β in epithelial and lymphoid cells
49. Inducible phosphorylation of IκBα is not sufficient for its dissociation from NF-κB and is inhibited by protease inhibitors
50. Studies into the effect of the tyrosine kinase inhibitor herbimycin A on NF-κB activation in T lymphocytes: Evidence for covalent modification of the p50 subunit
51. Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-κB
52. Differential IκB kinase activation and IκBα degradation by interleukin-1β and tumor necrosis factor-α in human U937 monocytic cells: Evidence for additional regulatory steps in κB-dependent transcription
53. Differential effect of thalidomide and dexamethasone on the transcription factor NF-κB
54. Inhibition of NF-κB activity by thalidomide through suppression of IκB kinase activity
55. rsk) phosphorylates the N-terminal regulatory domain of IκBα and stimulates its degradation in vitro
56. IκBα is a target for the mitogen-activated 90 kDa ribosomal S6 kinase
57. Inhibition of NF-κB DNA binding and nitric oxide induction in human T cells and lung adenocarcinoma cells by selenite treatment
58. Thioredoxin regulates the DNA binding activity of NF-κB by reduction of a disulphide bond involving cysteine 62
59. Thalidomide exerts its inhibitory action on tumor necrosis factor α by enhancing mRNA degradation
60. Binding of thalidomide to α1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor α production
61. Thalidomide reduces tumour necrosis factor-α production by human alveolar macrophages
62. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-α
63. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor α-dependent angiogenesis
64. Role of NF-κB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2
65. Activation of the transcription factor nuclear factor-κB in human inflamed synovial tissue
66. Cell specific effects of glucocorticoid treatment on the NF-κBp65/IκBα system in patients with Crohn's disease
67. Thalidomide analogue CC1069 inhibits development of rat adjuvant arthritis
68. Continuous low dose thalidomide: A phase II study in advanced melanoma, renal cell, ovarian and breast cancer
69. Thalidomide: Current and potential clinical applications
70. Thalidomide as an emerging immunotherapeutic agent